Clinical Trials Logo
  1. Home
  2. Lung Injury, Acute
  3. NCT01640990

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers

Lung Injury, Acute Clinical Trial

Official title:
A Single-centre, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Slow Intravenous Infusion of GW328267X in Healthy Volunteers

Clinical Trial Summary

This study is a single dose evaluation using an open label dose escalating design. Cohort1 will consist of 3 healthy male volunteers. Each volunteer will receive a slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg) and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg). Subjects will have continuous cardiac monitoring throughout the dosing period and up to 2 hours after cessation of the intravenous infusion. PK measurements and measurement of erythropoietin and platelet activation will also be done. Samples for PK will be taken at 30 minute intervals during the infusion of GW328267X up to and including 1 hour after cessation of the intravenous infusion. Samples for erythropoietin and platelet aggregation will be done.

Cohort 2 is optional and may be carried out in the event that the dose of GW328267X given in Cohort 1 is both well tolerated and subjects do not meet the stopping criteria. The decision to proceed to Cohort 2 and the dose level will be made by the GSK Study Team and the Investigator based on safety, tolerability and preliminary PK/PD data obtained in Cohort 1. It is planned that the maximum total dose given to any subject will not exceed 150mcg. Cohort 2 will consist of 3 healthy male volunteers and the study procedures for this additional Cohort will be the same as that described for Cohort 1.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01640990
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date November 22, 2011
Completion date December 9, 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT00498251 - Prevention of Lung Edema After Thoracic Surgery N/A
Completed NCT01597635 - The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury Phase 2
Completed NCT00141726 - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Phase 2
Completed NCT00996840 - SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS Phase 2
Completed NCT03651817 - Lung Protection Strategy in Open Heart Surgery: Which Tidal Volume is Better 8ml/kg or 6ml/kg N/A
Recruiting NCT05680831 - Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air Phase 1
Completed NCT03764319 - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO N/A
Completed NCT01114009 - Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients N/A
Terminated NCT00715338 - Effects of Oxygen on Lung Tissue During Anesthesia N/A
Recruiting NCT03202641 - Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients N/A
Completed NCT03828630 - Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients
Completed NCT03905837 - Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery Phase 4
Completed NCT03023670 - Lung Protection and Pediatric Cardiac Surgery N/A
Recruiting NCT05647967 - Features of Regional Perfusion of Lung Consolidation
Recruiting NCT04289324 - Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants N/A
Completed NCT05610475 - Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass N/A
Completed NCT05647382 - Soluble VE-cadherin in Prediction and Diagnosis of Early Postoperative Hypoxemia After Cardiopulmonary Bypass N/A
Recruiting NCT04511923 - Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury Phase 1/Phase 2
Active, not recruiting NCT03637530 - a Study Conducted About a New Mode of Ventilation in Laparoscopic Surgeries N/A
Completed NCT04344184 - SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) Phase 2